GS 626510
Alternative Names: GS-626510; GS-6510Latest Information Update: 28 Jan 2022
At a glance
- Originator Gilead Sciences
- Class Antineoplastics
- Mechanism of Action BRD4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Diffuse large B cell lymphoma
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 09 Dec 2017 Preclinical trials in Diffuse large B cell lymphoma in USA (Parenteral)